Although specificity of the pharmacological intervention would rest on selective targeting the striatal astrocytic vs neuronal A2A-D2 heteromers, blockade of the astrocytic A2A receptor might be predicted to have a greater impact on glutamate transmission regulation, when one considers the high expression of A2A receptors in PD [55,56], the colocalization of ectonucleotidases—producing adenosine from extracellular ATP—with the striatal astrocytic A2A receptors [57], and the expansion of the striatal perisynaptic processes in PD. The gene discussed is IGKV2D-29; the disease is Parkinson disease.